Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphocytic Leukemia
Clofarabine's interim results in leukemia reported at symposium
April 19th, 2005
Bioenvision (BIVN) announced interim results from the ongoing clinical studies of clofarabine in pediatric and adult acute leukemia trials which, the company states, confirm clofarabine's outstanding profile observed in previous studies. Clofarabine has recently been approved by the U.S. Food and Drug Administration (FDA) in the U.S. for the treatment of relapsed/refractory pediatric acute lymphocytic leukemia (ALL). Professors Alan K. Burnett and Varsha Ghandhi presented data from clofarabine's ongoing clinical development program at the sixth International Symposium and Expert Workshops on Leukemia and Lymphoma in Amsterdam, Netherlands, March...
Source: Cancer Weekly (2005-04-19)
|
